Compstatin analogues and their medical uses

A method of inhibiting complement activation for treating a subject in need thereof, the method comprising administering to the subject a compstatin analogue of Formula I:

• (SEQ ID NO:
• 2)
• Y1-R1-X1-C-I-X4-Q-X6-W-X8-E-H-X11-C-X13-R2-Y2
• (Formula I)
• wherein:
• Y1 is hydrogen, acetyl or a lipophilic group φ;
• X1 is I, Y, F or Sar;
• X4 is W, F, V, Y, 1-Me-Trp, D-Trp, N-Me-Trp, 1-For-Trp, 1-Nal, 2-Nal, 5-Me-Trp, Bpa or 2-Igl;
• X6 is E, K or D;
• X8 is G or Sar;
• X11 is R, S or K;
• X13 is T, S, E, F, H, K, Sar, G, I, D, N-Me-Ile or N-Me-Thr;
• Y2 is NH2, OH or a lipophilic group φ;
• R1 is absent or is a sequence of 1 to 6 amino acid residues selected from the group consisting of A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp, βAla, or a corresponding D form thereof;
• Peg3, Peg4, and 8-aminooctanoyl;
• and
• R2 is absent or is a sequence of 1 to 8 amino acid residues selected from the group consisting of A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp, βAla, or a corresponding D form thereof;
• Peg3, Peg4, and 8-aminooctanoyl;
• wherein the compstatin analogue has a disulphide bond between the cysteine residues at positions 2 and 12;
• and wherein the compstatin analogue optionally has a lipophilic group φ covalently linked to the side chain of one or more amino acid residues;
• or a pharmaceutically acceptable salt thereof, thereby to inhibit complement activation in the subject.